Edwards Lifesciences (NYSE:EW) Issues FY 2026 Earnings Guidance

23 Jan 2026, 07:00 by Doug Wharley · The Cerbat Gem

Edwards Lifesciences (NYSE:EW – Get Free Report) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 2.900-3.050 for the period, compared to the consensus estimate of 2.870. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. National Bankshares set a $92.00 price target on Edwards Lifesciences in a research report on Friday, October 31st. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, December 17th. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday. Finally, Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target on the stock in a research note on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.82.

Read Our Latest Research Report on EW

Edwards Lifesciences Stock Down 0.9%

Shares of NYSE EW opened at $84.41 on Friday. Edwards Lifesciences has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $48.98 billion, a price-to-earnings ratio of 36.38, a price-to-earnings-growth ratio of 3.25 and a beta of 0.95. The firm has a 50-day moving average price of $85.04 and a 200 day moving average price of $80.75.

Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. Edwards Lifesciences’s revenue was up 14.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the sale, the vice president directly owned 38,970 shares in the company, valued at $3,264,127.20. This trade represents a 22.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 57,824 shares of company stock worth $4,863,323 in the last ninety days. 1.29% of the stock is owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently made changes to their positions in the company. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $266,000. NewEdge Advisors LLC lifted its holdings in Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. grew its holdings in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC raised its position in shares of Edwards Lifesciences by 277.7% in the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after purchasing an additional 50,924 shares during the period. Finally, Treasurer of the State of North Carolina lifted its stake in shares of Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after buying an additional 1,065 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

(Get Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.